News
Rein is working to begin U.K. enrollment for its Phase 2 trial of LTI-03, a candidate therapy for IPF, after receiving ...
Consistently tracking KL-6 levels may help predict acute exacerbations in IPF and other types of fibrotic ILDs, a study ...
Columnist Sam Kirton takes readers on his journey from a pulmonary function test to his results from lung biopsies that weren't routine.
How do you want to be remembered after your passing? Columnist Sam Kirton shares the steps he's taking to leave a positive legacy.
GRI-0621 appears to reduce markers of fibrosis in people with idiopathic pulmonary fibrosis, interim clinical trial data suggest.
Researchers in China used machine learning to create diagnostic and prognostic models to aid in identifying idiopathic pulmonary fibrosis.
Columnist Sam Kirton describes how daunting an IPF prognosis can be — but also how things are looking up for patients today.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results